Neupogen News
Most Popular Neupogen Story
Analysts: Amgen most at risk from biogenerics
No drugmaker stands to lose more to biotech copycat drugs than Amgen. Analysts think its blockbuster blood-cell boosters Epogen and Neupogen will be among the first drugs copied in the U.S., once Read more...
Latest Headlines
- December 2, 2009
- July 17, 2009
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
